With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
This was a very surprising outcome after very strong phase 1b results and the success of competitor Cobenfy in clinical ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
The long-term trials indicated that COBENFY maintained its efficacy in reducing schizophrenia symptoms such as hallucinations, delusions, and social withdrawal. The EMERGENT-4 trial, an open-label ...
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
At the same time, Bristol’s Cobenfy approval adds to the firm’s wide moat established with its strong oncology and cardiovascular foundation. Following the emraclidine trial failures ...
People with schizophrenia now have a new drug to treat the neuropsychiatric condition. Cobenfy, which comes in capsule form, works on the muscarinic nervous system, a different network from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback